Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mathilde Borg Houlberg Thomsen"'
Autor:
Pernille B. Elming, Thomas R. Wittenborn, Morten Busk, Brita S. Sørensen, Mathilde Borg Houlberg Thomsen, Trine Strandgaard, Lars Dyrskjøt, Steffen Nielsen, Michael R. Horsman
Publikováno v:
Cancers, Vol 13, Iss 11, p 2602 (2021)
Background: This pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in
Externí odkaz:
https://doaj.org/article/ab85b487c9224430affa49a579f205ff
Autor:
Lars Dyrskjøt, Torben F. Ørntoft, Jakob Skou Pedersen, Søren Høyer, Jørgen Bjerggaard Jensen, Michael Borre, Jakob Hedegaard, Søren Vang, Palle Villesen, Mathilde Borg Houlberg Thomsen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Philippe Lamy
Mutations included in the 1530 amplicons target panel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a605cc8cce7e8b9fdb74fea49839889a
https://doi.org/10.1158/0008-5472.22413740
https://doi.org/10.1158/0008-5472.22413740
Autor:
Lars Dyrskjøt, Torben F. Ørntoft, Jakob Skou Pedersen, Søren Høyer, Jørgen Bjerggaard Jensen, Michael Borre, Jakob Hedegaard, Søren Vang, Palle Villesen, Mathilde Borg Houlberg Thomsen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Philippe Lamy
Legend for Supplementary Tables S1-S6 and Supplementary Figures S1-S19.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60bd67dd5a02a0064ba7a5845f53d97c
https://doi.org/10.1158/0008-5472.22413734
https://doi.org/10.1158/0008-5472.22413734
Autor:
Lars Dyrskjøt, Torben F. Ørntoft, Jakob Skou Pedersen, Søren Høyer, Jørgen Bjerggaard Jensen, Michael Borre, Jakob Hedegaard, Søren Vang, Palle Villesen, Mathilde Borg Houlberg Thomsen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Philippe Lamy
Greater knowledge concerning tumor heterogeneity and clonality is needed to determine the impact of targeted treatment in the setting of bladder cancer. In this study, we performed whole-exome, transcriptome, and deep-focused sequencing of metachrono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35174964cb987a99c977cd759a020b47
https://doi.org/10.1158/0008-5472.c.6508802.v1
https://doi.org/10.1158/0008-5472.c.6508802.v1
Autor:
Lars Dyrskjøt, Torben F. Ørntoft, Jakob Skou Pedersen, Søren Høyer, Jørgen Bjerggaard Jensen, Michael Borre, Jakob Hedegaard, Søren Vang, Palle Villesen, Mathilde Borg Houlberg Thomsen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Philippe Lamy
Description of additional methods and procedures used in the study. Also includes Supplementary References.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a148adbb9b7e888808b5a98661b0f11
https://doi.org/10.1158/0008-5472.22413755.v1
https://doi.org/10.1158/0008-5472.22413755.v1
Autor:
Michael Borre, Lars Dyrskjøt, Philippe Lamy, Iver Nordentoft, Søren Høyer, Torben F. Ørntoft, Mathilde Borg Houlberg Thomsen, Søren Vang, Jørgen Bjerggaard Jensen, Jakob Hedegaard
Publikováno v:
Thomsen, M B H, Nordentoft, I, Lamy, P, Høyer, S, Vang, S, Hedegaard, J, Borre, M, Jensen, J B, Ørntoft, T F & Dyrskjøt, L 2016, ' Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma ', Molecular Oncology, vol. 10, no. 9, pp. 1450-1460 . https://doi.org/10.1016/j.molonc.2016.08.003
Patients with metastatic bladder cancer have a median survival of only 13-14 months. Precision medicine using targeted therapy may improve survival. Here we investigated spatial and temporal tumour evolution and tumour heterogeneity in order to evalu
Autor:
Lars Dyrskjøt, Christophe K. Mapendano, Torben F. Ørntoft, Iver Nordentoft, Jørgen Bjerggaard Jensen, Søren Høyer, Mathilde Borg Houlberg Thomsen, Philippe Lamy, Søren Vang, Line S. Reinert
Publikováno v:
Thomsen, M B H, Nordentoft, I, Lamy, P, Vang, S, Reinert, L, Mapendano, C K, Høyer, S, Ørntoft, T F, Jensen, J B & Dyrskjøt, L 2017, ' Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer ', Scientific Reports, vol. 7, no. 1, pp. 11702 . https://doi.org/10.1038/s41598-017-11291-0
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports
Genetic alterations identified in adjacent normal appearing tissue in bladder cancer patients are indicative of a field disease. Here we assessed normal urothelium transformation and intra-tumour heterogeneity (ITH) in four patients with bladder canc
Autor:
Palle Villesen, Lars Dyrskjøt, Torben F. Ørntoft, Søren Høyer, Iver Nordentoft, Jakob Skou Pedersen, Søren Vang, Michael Borre, Karin Birkenkamp-Demtröder, Philippe Lamy, Jørgen Bjerggaard Jensen, Mathilde Borg Houlberg Thomsen, Jakob Hedegaard
Publikováno v:
Lamy, P, Nordentoft, I K, Birkenkamp-Demtröder, K, Thomsen, M B H, Villesen, P, Vang, S, Hedegaard, J, Borre, M, Jensen, J B, Ørntoft, T F & Andersen, L D 2016, ' Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma ', Cancer Research, pp. 5894-5906 . https://doi.org/10.1158/0008-5472.CAN-16-0436
Greater knowledge concerning tumor heterogeneity and clonality is needed to determine the impact of targeted treatment in the setting of bladder cancer. In this study, we performed whole-exome, transcriptome, and deep-focused sequencing of metachrono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a306ddf20081f9c596b3f62be58e66b
https://pure.au.dk/portal/da/publications/paired-exome-analysis-reveals-clonal-evolution-and-potential-therapeutic-targets-in-urothelial-carcinoma(69ff974d-9755-4ac6-9ccf-0d9323964922).html
https://pure.au.dk/portal/da/publications/paired-exome-analysis-reveals-clonal-evolution-and-potential-therapeutic-targets-in-urothelial-carcinoma(69ff974d-9755-4ac6-9ccf-0d9323964922).html
Autor:
Lars Dyrskjøt, Michael Borre, Karin Mogensen, Torben F. Ørntoft, Roman Nawroth, Gregers G. Hermann, Jørgen Bjerggaard Jensen, Núria Malats, Mattias Höglund, Philippe Lamy, Ewout W. Steyerberg, Sven Wach, Ellen C. Zwarthoff, Tatjana Simic, Kerstin Junker, Jakob Skou Pedersen, Astrid Christine Petersen, Mathilde Borg Houlberg Thomsen, Arndt Hartmann, Ferran Algaba, Karin Birkenkamp-Demtröder, M. Luz Calle, Jakob Hedegaard, Niels Fristrup, Kim E.M. van Kessel, Per-Uno Malmström, Bastian Keck, Cane Tulic, Søren Vang, Iver Nordentoft, Søren Høyer, Willemien Beukers, Francisco X. Real, Robert Stöhr, Tobias Maurer, Anna Katharina Seitz, Benedicte Parm Ulhøi, Marcus Horstmann, Ulrika Segersten, Mirari Marquez, Thomas Reinert, Morten Muhlig Nielsen, Niels Harving, Mattias Aine
Publikováno v:
Hedegaard, J, Lamy, P, Nordentoft, I, Algaba, F, Høyer, S, Ulhøi, B P, Vang, S, Reinert, T, Hermann, G G, Mogensen, K, Thomsen, M B H, Nielsen, M M, Marquez, M, Segersten, U, Aine, M, Höglund, M, Birkenkamp-Demtröder, K, Fristrup, N, Borre, M, Hartmann, A, Stöhr, R, Wach, S, Keck, B, Seitz, A K, Nawroth, R, Maurer, T, Tulic, C, Simic, T, Junker, K, Horstmann, M, Harving, N, Petersen, A C, Calle, M L, Steyerberg, E W, Beukers, W, van Kessel, K E M, Jensen, J B, Pedersen, J S, Malmström, P-U, Malats, N, Real, F X, Zwarthoff, E C, Ørntoft, T F & Dyrskjøt, L 2016, ' Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma ', Cancer Cell, vol. 30, no. 1, pp. 27-42 . https://doi.org/10.1016/j.ccell.2016.05.004
Cancer Cell, 30(1), 27-42. Cell Press
Hedegaard, J, Lamy, P, Nordentoft, I, Algaba, F, Høyer, S, Ulhøi, B P, Vang, S, Reinert, T, Hermann, G G, Mogensen, K, Thomsen, M B H, Nielsen, M M, Marquez, M, Segersten, U, Aine, M, Höglund, M, Birkenkamp-Demtröder, K, Fristrup, N, Borre, M, Hartmann, A, Stöhr, R, Wach, S, Keck, B, Seitz, A K, Nawroth, R, Maurer, T, Tulic, C, Simic, T, Junker, K, Horstmann, M, Harving, N, Petersen, A C, Calle, M L, Steyerberg, E W, Beukers, W, van Kessel, K E M, Jensen, J B, Pedersen, J S, Malmström, P-U, Malats, N, Real, F X, Zwarthoff, E C, Ørntoft, T F & Dyrskjøt, L 2016, ' Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma ', Cancer Cell, vol. 30, no. 1, pp. 27–42 . https://doi.org/10.1016/j.ccell.2016.05.004
CANCER CELL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cancer Cell, 30(1), 27-42. Cell Press
Hedegaard, J, Lamy, P, Nordentoft, I, Algaba, F, Høyer, S, Ulhøi, B P, Vang, S, Reinert, T, Hermann, G G, Mogensen, K, Thomsen, M B H, Nielsen, M M, Marquez, M, Segersten, U, Aine, M, Höglund, M, Birkenkamp-Demtröder, K, Fristrup, N, Borre, M, Hartmann, A, Stöhr, R, Wach, S, Keck, B, Seitz, A K, Nawroth, R, Maurer, T, Tulic, C, Simic, T, Junker, K, Horstmann, M, Harving, N, Petersen, A C, Calle, M L, Steyerberg, E W, Beukers, W, van Kessel, K E M, Jensen, J B, Pedersen, J S, Malmström, P-U, Malats, N, Real, F X, Zwarthoff, E C, Ørntoft, T F & Dyrskjøt, L 2016, ' Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma ', Cancer Cell, vol. 30, no. 1, pp. 27–42 . https://doi.org/10.1016/j.ccell.2016.05.004
CANCER CELL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into three ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::982a3ccc750a98100bed57ceb2863b2f
https://vbn.aau.dk/da/publications/2c9845c8-f9a6-44e7-aff7-cb4e3d7e9220
https://vbn.aau.dk/da/publications/2c9845c8-f9a6-44e7-aff7-cb4e3d7e9220
Autor:
Lars Dyrskjøt, Torben F. Ørntoft, Line S. Reinert, Philippe Lamy, Jørgen Bjerggaard Jensen, Søren Høyer, Mathilde Borg Houlberg Thomsen, Søren Vang, Iver Nordentoft
Publikováno v:
Cancer Research. 77:3948-3948
Background: Bladder cancer is a highly heterogeneous disease - both clinically, and at the genomic and the transcriptomic levels. Despite complete tumor resections, recurrent tumors share a high number of mutations with the initial/earlier tumors, in